Approved overseas for the first time! Ganli Pharmaceutical's insulin lispro obtained drug registration approval in Lebanon

August 25, 2021

Recently, Ganli Pharmaceutical Co., Ltd. (hereinafter referred to as "Ganli Pharmaceutical", stock code: 603087.SH) insulin lispro injection obtained drug registration approval in Lebanon. This is the first overseas approval for insulin lispro independently developed by Ganli Pharmaceutical, and it is also the in-depth commercial expansion of product diversification following the company's formal commercialization of insulin glargine injection in Lebanon. As a quick-acting meal insulin, insulin lispro has high flexibility in medication and quick onset of action. According to the Standards of Medical Care in Diabetes (2021) issued by the American Diabetes Association, the combination of mealtime insulin and basal insulin can simulate physiological insulin secretion and is suitable for non-critically ill hospitalized patients. Among the 20-79-year-old adult population, the number of diabetes patients in Lebanon is approximately 530,000, with a prevalence rate of 12.9%. The approval of insulin lispro will provide Lebanese patients with diversified high-quality medication options. As the only Chinese high-tech biopharmaceutical company that mainly exports insulin analogues in the world, Ganli Pharmaceutical has established an international commercial network in more than 20 countries and regions around the world since 2005. In recent years, the company has continuously deepened overseas cooperation and has made breakthroughs one after another. The company has signed cooperation agreements with customers in many countries, and opened the overseas registration of insulin drugs and medical devices across the board.

前

お問い合わせ

Author:

Ms. Yi

Phone/WhatsApp:

+8618888297294